Recombinant Human Thrombopoietin Reduces the Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia
American Journal of Hematology · 2026-10 · 101 (10) · 2571-2580
DOI: 10.1002/ajh.70444 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Hematology, online erschienen am 28.07.2026. Verfasst von Yifan Han und 45 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Thrombocytopenia, Thrombopoietin, Platelet Transfusion, Liver Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Prevention and Control of Emerging and Major Infectious Diseases-National Science and Technology Major Project, Beijing iGandan Foundation.
Abstract (Originalsprache)
Chronic liver disease (CLD)‐related thrombocytopenia can limit the feasibility of invasive procedures. Recombinant human thrombopoietin (rhTPO) has demonstrated a favorable safety profile without hepatotoxicity. We evaluated the efficacy and safety of rhTPO in patients with CLD‐related thrombocytopenia who were undergoing elective invasive procedures. In this multicenter, randomized (2:1), double‐blind, placebo‐controlled phase III trial, 120 adult Chinese patients with CLD‐related thrombocytopenia (platelet count < 50 × 10 9 /L) received rhTPO ( n = 80) or placebo ( n = 40) once daily for up to 5 or 7 days. The primary endpoint was the proportion of patients with sustained platelet counts ≥ 50 × 10 9 /L from 24 h before invasive procedure to 7 days post‐procedure, without requiring emergency bleeding management. The primary endpoint was achieved by 85.0% of patients in the rhTPO group versus 12.5% in the placebo group ( p < 0.0001). Preoperatively, platelet counts ≥ 50 × 10 9 /L were achieved in 92.5% and 20.0% of patients in the rhTPO and placebo groups, respectively ( p < 0.0001). Platelet transfusion was avoided in 92.5% of rhTPO‐treated patients versus 25.0% of placebo‐treated patients ( p < 0.0001). The median duration of platelet counts ≥ 50 × 10 9 /L was significantly longer with rhTPO than with placebo (21.0 vs. 3.0 days, p = 0.0007). Treatment‐related treatment‐emergent adverse events (TEAEs) occurred in 12.5% of patients in both the rhTPO and placebo groups. No treatment‐related serious adverse events were reported. Overall, rhTPO was effective and well tolerated in patients with CLD‐related thrombocytopenia and may represent a viable therapeutic option for those undergoing elective invasive procedures. Trial Registration: www.chinadrugtrials.org.cn : number CTR20230919.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Peking University First Hospital, Beijing, China.
- Department of Infectious Diseases, Peking University First Hospital, Beijing, China.
- Department of Infectious Disease, Liaocheng People's Hospital, Shandong, China.
- Department of Hepatology, The First Hospital of Jilin University, Jilin, China.
- Department of Infectious Diseases, Henan Provincial People's Hospital, Henan, China.
- Department of Hepatology, Qingdao Municipal Hospital, Shandong, China.
ORCID-Profile: Yifan Han, Ning Lin, Jinghang Xu, Yongning Xin, Youwen Tan, Jinlin Hou, Wen Xie, Huiguo Ding, Rongkuan Li, Mingqin Lu, Yongjian Zhou, Yuemin Nan, Tao Han, Kai Wang, Jun Chen, Xiaoyuan Xu
Förderung
- Prevention and Control of Emerging and Major Infectious Diseases-National Science and Technology Major Project
- Beijing iGandan Foundation
Zitieren
APA
Han, Y., Lin, N., Xu, J., Wang, S., Jin, J., Shang, J., Xin, Y., Tan, Y., Zhang, D., Hou, J., An, P., Xie, W., Guan, Y., Xiong, Q., Wu, H., Ding, H., Chen, Y., Li, R., Wen, Z., …, & Xu, X. (2026). Recombinant Human Thrombopoietin Reduces the Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia. American Journal of Hematology, 101(10), 2571-2580. https://doi.org/10.1002/ajh.70444
Vancouver
Han Y, Lin N, Xu J, Wang S, Jin J, Shang J, et al. Recombinant Human Thrombopoietin Reduces the Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia. American Journal of Hematology. 2026;101(10):2571-2580. doi:10.1002/ajh.70444
BibTeX
@article{Han2026,
author = {Han, Yifan and Lin, Ning and Xu, Jinghang and Wang, Sikui and Jin, Jinglan and Shang, Jia and Xin, Yongning and Tan, Youwen and Zhang, Dazhi and Hou, Jinlin and An, Ping and Xie, Wen and Guan, Yujuan and Xiong, Qingfang and Wu, Hong and Ding, Huiguo and Chen, Yu and Li, Rongkuan and Wen, Zhili and Lu, Mingqin and Yang, Jinhui and Zhou, Zhongyin and Zhou, Yongjian and Yu, Zujiang and Lin, Kecan and Wang, Wei and Huang, Yan and Nan, Yuemin and Luo, Xinhua and Shi, Rongshu and Kang, Yi and Han, Tao and Chen, Shiyan and Wang, Kai and Shan, Yunfeng and Li, Jiaping and Liu, Pingguo and Lu, Zheng and Chen, Jun and Liu, Zhen and Zhang, Liaoyun and Yang, Li and Sheng, Jifang and Zeng, Zhan and Yu, Yanyan and Xu, Xiaoyuan},
title = {Recombinant Human Thrombopoietin Reduces the Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia},
journal = {American Journal of Hematology},
year = {2026},
volume = {101},
number = {10},
pages = {2571--2580},
doi = {10.1002/ajh.70444}
}
EUVIMED